

Introduction & Notes re: MVB Annual Assessment Setting Workbook

MVB Calendar Year 2019

[Note: This is a Working Version as of 9/13/2018.

01. This workbook follows the past naming conventions with each sheet beginning with a letter (i.e., "a." through "d."), and each cell within each sheet being identified by a 2-digit row number (e.g., "01.") and column letter (e.g., "A"). So, to facilitate reference while collaborating via conference phone, users can refer to any single number, for example the new assessment rate, by a combination of the above. For that key number, the new monthly assessment rate, the reference is "a.26.C".
02. Since the first measurement period is for the month of January and assessments are due forty-five (45) days after the end of each quarter, the first assessment payment with the new rate will be May 15, 2019 for the months of Jan-Mar, 2019.
03. The primary spreadsheet for the work is the assessment calculation worksheet, worksheet a. The other sheets are intended to be reference or to develop background data in specific areas for the work. Key data for developing the primary funding target is on spreadsheet b. which contains data supplied by the Maine CDC for the vaccine funding needs. Key numbers from a subsidiary sheet rolled into the main assessment sheet generally are shaded in yellow.
04. These spreadsheets are protected as published. This is intended to help users test various assumptions and control points which may be adjusted by the MVB in setting the final new rate. Those cells in which entries normally would be made are shaded in green. They are unprotected to allow data entry. For example, a user can adjust utilization assumptions for increases over prior years by entering percent's either by vaccine on sheet b. or overall on sheet a (a.3.C). The vaccine funding target takes the number as adjusted by those two factors and then applies the assumed cost increase (a.4.D). The cost increase is applied for 9/12 of the year since it typically becomes effective as of April 1 each year. The protection password to unlock the spreadsheet, for those who may wish to do so, is "KidsVax". Please note: It is not necessary to unlock the spreadsheet to see the underlying formulas. Those are displayed in the formula bar whenever the cursor is placed on a cell, whether or not the sheet is unprotected.
05. Because the first collections of the year (due February 15) will still be at the old rate and based upon covered lives reported for Oct-Dec 2018, this spreadsheet first deducts that quarterly collection and then calculates the new rate based upon what is needed to hit the funding target over the remaining 9 months.
06. It is anticipated that the MVB will, as part of its deliberations and upon considering the input of any public members or others at its meeting(s), adjust the assumptions which guide the assessment level. Of course, the MVB may also determine to adjust the assessment setting process itself or this workbook structure at any time.

Maine Vaccine Board

2019 Calendar Year Assessment Calculation

Column →	A	B	C	D	E
Line ↓	2018		2019		
A. Preliminary Vaccine Cost, Projection Parameters, & Population Estimates					
01.	\$11,991,752		\$11,324,363		State Fiscal Year Vaccine Estimate (from tab b.)
02.	136,857		140,088		Estimate of Covered Lives including Tricare(Covered Lives tab c.)
03.	\$119,918	1.0%	\$113,244	1.0%	Provision for Vaccine Utilization increase
04.	\$317,931	3.5%	\$403,176	4.7%	Vaccine cost inflation factor (prices change each April 1st)
05.	\$12,429,601		\$11,840,782		¹ Calendar Year Vaccine Funding Estimate
B. Budget Estimates					
06.	\$153,081		\$149,040		³ Servicing Agent Contract for Administrative Services
07.	\$6,000		\$6,000		Audit Fee (Move to paid public auditor & 2 years catch up fees)
08.	\$5,500		\$6,000		Bank Fees (adding TD Bank Lockbox including setup expenses)
09.	\$5,500		\$5,500		Legal (services of AG's office only estimated)
10.	\$170,081		\$166,540		Total Operating Costs Projected
C. Financial Carry Forwards					
11.	\$5,191,172		\$9,830,939		Estimated Starting Balance January 1
12.	\$2,864,958		\$5,749,100	6.4	Amount Retained for Liquidity Reserve - 6.4 months of non flu
13.	\$969,770		\$1,061,220		Amount Retained for Liquidity Reserve - full annual flu cost
14.	\$1,356,445		\$3,020,620		Carryforward used to reduce current assessment calculation
D. Aggregate Annual Assessment Calculation					
15.	\$12,429,601		\$11,840,782		Costs of Vaccines Provided
16.	\$170,081		\$166,540		Total Operating Costs
17.	\$0		\$0		Other (as approved by board -- see statute section 2.M)
18.	\$12,599,682		\$12,007,322		"Total Costs of the Fund" per statute section 2.M.
19.	\$44,099	0.35%	\$42,026	0.35%	Collection Losses (i.e. assumed "bad debt expense")
20.	-\$55,571		-\$68,235		² Interest Income
21.	-\$1,356,445	-10.8%	-\$3,020,620	-25.2%	(excess) or shortfall of cash from prior operating year
22.	\$283,493	2.25%	\$270,165	2.25%	add reserve up to 10% per statute section 5.A.(3).
23.	\$11,515,257		\$9,230,658		Total Assessments Needed
24.	-\$1,301,510		-\$3,484,950		Projected assessments February 15 at old rate
25.	\$10,213,747		\$5,745,708		Total Assessments Needed at new rate
E. Per Covered Life Assessment Calculation					
26.	\$99.51		\$54.69		Annual Assessment per Covered Life
27.	\$8.29		\$4.56		Monthly Assessment per Covered Life
28.	2.0%		-5.6%		% Change in Vaccine Costs
29.	161.59%		-45.0%		% Change in Assessment
F. Note: Total Assessed as % of Hard Vaccine Costs					
30.	-7.36%		-22.0%		All-in costs % above vaccine costs
G. Indicated Monthly Assessment Level next year apart from reserve / cash changes					
31.	\$8.05		\$6.33		⁴ Preliminary Assessment projection
Notes			38.9%		Increase in preliminary assessment projection

¹ Maine CDC + per vaccine adjustments + utilization increase with inflation factor.

² Used the average of the four most recent year's Investment Income from audited financials.

³ Fixed price contract all inclusive of expenses.

⁴ Projection: annual amounts w/o carryforward cash or reserve changes but 1 more year of inflation & utilization changes.

Maine CDC Vaccine Projection Data

Column →	A	B	C	D	E	F	G	H	I	J	K	
Line ↓	Vaccine	Brand Name	NDC	Prior Year Actuals			Federal FY 19 Estimates			Vaccine Level Adjustments	Vaccine Funding Target	
				Cost Per Dose	Doses	Cost	Cost Per Dose	Doses	Cost			
01.	DAPTACEL	Sanofi Pasteur	49281-0286-10	\$ 17.16	3729	\$ 63,989.64	\$17.61	3,989	\$70,246	0.00%	\$70,246	
1.b				\$ 17.61	1364	\$ 24,020.04						
02.	PENTACEL	Sanofi Pasteur	49281-0510-05	\$ 56.74	7436	\$ 421,903.99	\$58.33	7,954	\$463,957	0.00%	\$463,957	
2.b				\$ 58.33	2754	\$ 160,640.82						
03.	QUADRACEL	Sanofi Pasteur	49281-0562-10	\$ 39.57	574	\$ 22,713.18	\$39.57	448	\$17,727		\$17,727	
04.	IPOL (EIPV)	Sanofi Pasteur	49281-0860-10	\$ 13.04	1237	\$ 16,130.48	\$13.30	171	\$2,274	0.00%	\$2,274	
4.b				\$ 13.30	431	\$ 5,732.30						
05.	Menactra (MCV4)	Sanofi Pasteur	49281-0589-05	\$ 89.16	7215	\$ 643,289.40	\$91.81	10,199	\$936,370	0.00%	\$936,370	
5.b				\$ 91.81	2542	\$ 233,381.02						
06.	ACTHIB (HIB)	Sanofi Pasteur	49281-0545-03	\$ 9.55	4149	\$ 39,622.95	\$9.23	282	\$2,603	0.00%	\$2,603	
6.b				\$ 9.23	1289	\$ 11,897.47						
07.	ADACEL (Tdap)	Sanofi Pasteur	49281-0400-10	\$ 30.99	1979	\$ 61,329.21	\$30.89	2,827	\$87,326	0.00%	\$87,326	
7.b				\$ 30.89	554	\$ 17,113.06						
08.	Prevnar 13 (PCV 13)	Pfizer	00005-1971-02	\$ 126.97	15384	\$ 1,953,306.48	\$131.77	14,734	\$1,941,499	0.00%	\$1,941,499	
8.b				\$ 131.77	5281	\$ 695,877.37						
09.	TRUMENBA (Menb)	Pfizer	00005-0100-10	\$ 100.98	192	\$ 19,388.16	\$104.79	640	\$67,066	\$0.00	\$67,066	
9.b				\$ 104.79	52	\$ 5,449.08						
10.	Bexsero (Menb)	GlaxoSmithKline	58160-0976-06	\$ 98.51	504	\$ 49,649.04	\$103.40	2,031	\$210,005	\$0.00	\$210,005	
10.b				\$ 129.06	269	\$ 34,717.14						
11.	MENVEO (MCV4)	GlaxoSmithKline	58160-0955-09	\$ 71.70	2247	\$ 161,109.90	\$73.83	3,135	\$231,457		\$231,457	
11.b				\$ 92.10	770	\$ 70,917.00						
12.	Infanrix (DTaP)	GlaxoSmithKline	58160-0810-11	\$ 17.73	553	\$ 9,805	\$18.19	511	\$9,295	0.00%	\$9,295	
12.b				\$ 18.19	101	\$ 1,837						
13.	Pediarix (DTaP/Hep B/IPV)	GlaxoSmithKline	58160-0811-52	\$ 56.43	4832	\$ 272,670	\$57.97	4,893	\$283,647	0.00%	\$283,647	
13.b				\$ 57.97	1437	\$ 83,303						
14.	Kinrix (DTaP/IPV)	GlaxoSmithKline	58160-0812-52	\$ 39.57	3625	\$ 143,441	\$40.19	3,865	\$155,334	0.00%	\$155,334	
15.	Havrix (Hep A)	GlaxoSmithKline	58160-0825-11	\$ 18.68	9881	\$ 184,577	\$19.58	10,725	\$209,996	0.00%	\$209,996	
16.	Engerix-B (Hep B)	GlaxoSmithKline	58160-0820-52	\$ 12.30	4767	\$ 58,634	\$14.03	6,896	\$96,751	0.00%	\$96,751	
17.	Engerix-B (Hep B)	GlaxoSmithKline	58160-0820-11	\$ 11.60	111	\$ 1,288	\$0.00	-				
18.	Rotarix (Rota)	GlaxoSmithKline	58160-0854-52	\$ 91.05	2941	\$ 267,778	\$92.85	2,566	\$238,253	0.00%	\$238,253	
18.b				\$ 92.85	999	\$ 92,757						
19.	Boostrix (TDaP)	GlaxoSmithKline	58160-0842-11	\$ 31.37	4114	\$ 129,056	\$31.37	5,801	\$181,977	0.00%	\$181,977	
19.b				\$ 31.67	1506	\$ 47,692						
20.	HIBERIX	GlaxoSmithKline	58160-0818-11	\$ 9.46	24	\$ 227	\$9.65	57	\$550	0.00%	\$550	
20.b				\$ 9.65	10	\$ 97						
21.	VAQTA (Hep A)	Merck Sharp & Dohme Corp.	00006-4831-41	\$ 18.75	2643	\$ 49,556	\$19.29	2,810	\$54,205	0.00%	\$54,205	
21.b				\$ 19.29	824	\$ 15,895						
22.	RECOMBIVAX (Hep B)	Merck Sharp & Dohme Corp.	00006-4981-00	\$ 12.30	1787	\$ 21,980	\$12.30	3,304	\$40,639	0.00%	\$40,639	
23.	PedvaxHib (Hib)	Merck Sharp & Dohme Corp.	00006-4897-00	\$ 12.79	3052	\$ 39,035	\$13.09	6,250	\$81,813	0.00%	\$81,813	
23.b				\$ 13.09	1138	\$ 14,896						
24.	Gardasil (HPV9)	Merck Sharp & Dohme Corp.	00006-4119-03	\$ 154.28	7916	\$ 1,221,280	\$168.10	18,435	\$3,098,924	0.00%	\$3,098,924	
24.b				\$ 148.54	3049	\$ 452,901						
24.b				\$ 168.10	3388	\$ 569,523						
25.	ROTATEQ (Rota)	Merck Sharp & Dohme Corp.	00006-4047-41	\$ 69.12	6353	\$ 439,119	\$70.49	5,539	\$390,444	0.00%	\$390,444	
25.b				\$ 70.49	2153	\$ 151,765						
26.	MMR II	Merck Sharp & Dohme Corp.	00006-4681-00	\$ 20.59	4551	\$ 93,705	\$21.05	3,210	\$67,571	0.00%	\$67,571	
26.b				\$ 21.05	1572	\$ 33,091						
27.	Proquad (MMRV)	Merck Sharp & Dohme Corp.	00006-4171-00	\$ 118.72	5580	\$ 662,458	\$125.11	4,791	\$599,402	0.00%	\$599,402	
27.b				\$ 125.11	3230	\$ 404,105						
28.	Pneumovax23 (Pedi)	Merck Sharp & Dohme Corp.	00006-4943-00	\$ 48.72	13	\$ 633	\$53.11	44	\$2,337	0.00%	\$2,337	
28.b				\$ 53.11	6	\$ 319						
29.	Varivax	Merck Sharp & Dohme Corp.	00006-4827-00	\$ 92.72	4200	\$ 389,424	\$98.24	7,344	\$721,475	0.00%	\$721,475	
29.b				\$ 98.24	2410	\$ 236,758						
				\$ -					\$0			
31.	Fluzone PF 0.5ml (>3 yrs)	Sanofi Pasteur	49281-0418-50	\$ 15.11	12830	\$ 193,861	\$15.11	13,000	\$196,430	0.00%	\$196,430	
32.	Fluzone PF 0.25ml (<3 yrs)	Sanofi Pasteur	49281-0518-25	\$ 15.11	8970	\$ 135,537	\$15.11	9,000	\$135,990	0.00%	\$135,990	
33.	Flulaval PF 0.5ml (6mth+)	GlaxoSmithKline	19515-0909-52	\$ 13.50	48330	\$ 652,455	\$13.50	40,000	\$540,000	0.00%	\$540,000	
34.	FluMist Quadrivalent	AstraZenca	66019-0305-10	\$ 18.88	2600	\$ 49,088	\$18.88	10,000	\$188,800		\$188,800	
						\$ 11,974,625			\$11,324,363	0.00%	\$11,324,363	
	TOTAL				227,734	\$ 11,974,625		205,451	\$11,324,363		\$11,324,363	
											Adjusted for overall utilization increase	\$11,437,606
											Adjusted for price increase	\$11,840,782

**Maine Vaccine Board
Vaccine Assessment Change Walk Down**

Column →	A	B	C	D	E	F	G
Line ↓	2019 Calendar Year Assessment Calculation						
			<u>Change from Prior Year</u>				<u>Walk Down</u>
	<u>Prior Year</u>	<u>2,019</u>	<u>Aggregate \$</u>	<u>Distribution</u>	<u>Per Enrollee</u>		
01. Estimated vaccine costs	\$12,429,601	\$11,840,782	-\$588,819	13.2%	-\$0.47		-5.6%
02. Total operational costs	\$170,081	\$166,540	-\$3,541	0.1%	\$0.00		0.0%
03. Bad debt and investment income	-\$11,472	-\$26,209	-\$14,737	0.3%	-\$0.01		-0.1%
04. Net working capital reserve/carry forward	-\$1,072,952	-\$2,750,455	-\$1,677,503	37.5%	-\$1.33		-16.0%
05. Projected assessment at old rate	<u>-\$1,301,510</u>	<u>-\$3,484,950</u>	<u>-\$2,183,440</u>	<u>48.9%</u>	<u>-\$1.73</u>		<u>-20.9%</u>
06. Total	\$10,213,747	\$5,745,708	-\$4,468,039	100.0%	-\$3.54		-42.7%
07. Covered Lives		136,857	140,088	3,231			-2.3%
08. Total							-45.0%
09. Assessment		\$8.29	\$4.56			-\$3.74	-45.0%